An experimental Alzheimer’s drug, donanemab, was endorsed by a U.S. Food and Drug Administration (FDA) advisory panel on Monday. Donanemab is designed to treat symptoms of early Alzheimer’s disease, ...

After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some novel drugs for the treatment of Alzheimer’s disease since 2021. Most of these drugs are antibody therapies ...

CHMP recommends Lilly's donanemab for early Alzheimer's in ApoE4 heterozygotes or non-carriers. TRAILBLAZER-ALZ trials show donanemab slowed cognitive decline and reduced disease progression risk. Get ...

The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today ...

INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment "We are confident that this ...

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and ...

Donanemab (Eli Lilly), an investigational anti-amyloid therapy, significantly slowed decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer's ...